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DNA was extracted from 52 thick primary melanomas and mutations sought in exon 15 of the BRAF (v-raf murine
sarcoma viral oncogene homolog B1) gene using denaturing high performance liquid chromatograph (dHPLC)
fragment analysis, sequencing, and allele-specific PCR. Exon 15 BRAF mutations were found in 13 of 52 (25%)
primary melanomas. These comprised ﬁve of 17 (29%) superﬁcial spreading melanomas, three of 11 (27%) nodular
melanomas, two of 13 (15%) acral lentiginous melanomas, one of one (100%) mucosal melanoma and two of 10
(20%) lentigo maligna melanomas. In common with other groups, our ﬁndings show a relative concentration of the
exon 15 BRAF mutation in superﬁcial spreading and nodular melanomas, but add further evidence that this mu-
tation not necessary for malignant transformation of the melanocyte.
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The BRAF (v-raf murine sarcoma viral oncogene homolog
B1) gene (MIM #164757) is situated on chromosome 7q34
(Eychene et al, 1992) and encodes a proto-oncogenic se-
rine/threonine-protein kinase. Its normal function is to con-
trol proliferation and differentiation through the MAP kinase
pathway.
Exon 15 BRAF mutations in melanoma were first report-
ed in 2002 and 80% of the mutations identified were a sin-
gle substitution of a neutral amino acid (valine at position
599 in exon 15) by a negatively charged one (usually glut-
amic acid) which is an activating mutation (Davies et al,
2002). The sequence numbering of the V599E is now
changed to V600E, as there is a discrepancy of one codon
in exon 1 in the BRAF gene sequence with accession
number NM_004333. The sequence analysis of exon 1 of
the BRAF gene by Kumar et al, 2003 has shown that the
sequence derived from NT_007914 is correct.
Davies et al studied melanoma lines and short-term cul-
tures but only nine samples of primary melanoma, six of
which contained the mutation. Other groups have therefore
sought to confirm the work of Davies with larger numbers of
primary tumor samples, and other relevant material. The
number of reports of BRAF mutations in primary melanoma
tissue is growing (Cruz et al, 2003; Dong et al, 2003; Omholt
et al, 2003; Pollock et al, 2003; Uribe et al, 2003; Yazdi et al,
2003; Reifenberger et al, 2004; Sasaki et al, 2004; Shinozaki
et al, 2004). These studies confirm the presence of BRAF
mutations but at very varying prevalences in primary me-
lanoma tissue which has led other groups to study primary
melanoma tissue from the four major histogenetic types to
see if there is any correlation between tumor type and the
presence or absence of BRAF mutations (Maldonado et al,
2003; Sasaki et al, 2004).
In this paper, we report our experience of exon 15 BRAF
mutations in the four major histogenetic subtypes of primary
melanoma.
Results
Fifty-seven samples were selected for DNA extraction. DNA
was successfully extracted and amplified from 52 of these
(Table I). The five samples in which amplification failed were
one superficial spreading melanoma, 3.5 mm thick from a
male back aged 72 y and four acral lentiginous melanomas
(AM), three from females and one from a male, all from the
foot. Their thicknesses ranged from 1.6 to 7.0 mm.
Thirteen abnormal chromatogram patterns as shown in
Fig 1, were identified on dHPLC for exon 15 and its flanking
sequences. On sequencing all samples, on two occasions,
ten of 13 samples showed the V600E substitution, (Fig 2)
and in three it was only observed on one sequence result.
All normal chromatogram patterns showed a wild-type se-
quence on both occasions. The allele-specific PCR con-
firmed the presence of the mutation in all 13 samples shown
to have an abnormal dHPLC chromatogram pattern, in-
cluding the three samples with one positive and one neg-
ative sequencing result. All samples negative on dHPLC and
on two sequencing results were also negative in the allele-Databases: BRAF—OMIM: 164757.
Abbreviations: AM, acral lentiginous melanoma; BRAF, v-raf murine
sarcoma viral oncogene homolog B1; NM, nodular melanoma;
LMM, lentigo maligna melanoma; SSM, superficial spreading me-
lanoma
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specific PCR. Thus, these data demonstrate in our hands
the greater sensitivity of dHPLC over sequencing.
The 13 samples in which we detected the V600E BRAF
mutation were five of seventeen (29%) superficial spreading
melanomas (SSM), three of 11 (27%) nodular melanomas
(NM), two of ten (20%) lentigo maligna melanomas (LMM)
and two of 13 (15%) AM. Nine of 29 (31%) samples from
male patients and four of 23 (17%) from female patients
were mutation positive (difference not significant). Six of 32
primary melanomas from constantly light-exposed sites
defined above carried the mutation (19%), and seven of 20
(35%) primaries from habitually covered sites contained the
mutation (difference not significant).
Discussion
This study adds a further 52 primary melanomas to those
already investigated for BRAF mutations. Although there are
currently 11 relevant papers in the literature, seven of these
have studied less than 50 samples (Table II). A further three
papers have reported on the consistently negative findings
in the search for BRAF mutations in mucosal melanomas
(Table III).
Pollock et al (2003) reported BRAF mutations in four of
five samples, and Cruz et al, 2003 found the BRAF mutation
in two of ten primary melanomas. Dong et al, 2003 found
BRAF mutations in five of eight (63%) vertical growth phase
melanomas, and two of 20 (10%) radial growth phase me-
lanomas. Uribe et al (2003) investigated the development of
BRAF mutations during malignant transformation of me-
lanocytes by examining DNA from 22 banal melanocytic
nevi, 23 atypical melanocytic nevi, and 25 primary cutane-
ous melanomas (13 SSM, three AM, two LMM, three NM,
and four unclassified melanomas) for BRAF mutations. Six-
teen of 22 banal nevi (73%), 11 of 23 atypical melanocytic
nevi (48%), and 13 of 25 melanomas (52%) had the V600E
mutation. In this paper, no information is given as to which
subtype of melanoma had the mutations, and no correlation
was found between BRAF mutational status and age, pres-
ence of primary on sun exposed or covered site, or Clark
level of invasion. Their findings of a high frequency of BRAF
mutations in benign melanocytic lesions confirm the previ-
ous observation by Pollock et al (2003) and also suggest
that a proportion of benign melanocytic lesions with little or
no recognized potential for progression to melanoma con-
tain a population of BRAF-mutated cells. Similarly, Yazdi
et al, 2003 in this journal detected BRAF mutations in 28 of
97 (29%) melanomas nevi, four of which were reported as
arising in a nevus and in 39 of 187 (21%). Thus the V600E
BRAF mutation alone appears not to be sufficient for ma-
lignant transformation of the nevus cell.
Shinozaki et al (2004) assessed BRAF mutation frequen-
cy in exons 11 and 15 in 59 primary and 68 metastatic
melanomas. They found 18 of 59 (31%) primary melanomas
to have a BRAF mutation in exon 15 with a significantly
higher frequency in patients o60 y old (p¼0.001). The in-
cidence of BRAF mutations did not correlate with Breslow
thickness.
Table III gives details of the findings in the four papers
currently in the literature, which like us have divided BRAF
findings by histogenetic type.
Omholt et al (2003) screened 71 primary melanomas and
88 corresponding metastases from 71 patients for BRAF
exon 11 and exon 15 mutations. Of the 71 primary me-
lanoma tumors, 40 were SSM, 28 NM, one LMM and two
were not classified. They identified mutations in 42 of 71
patients (59%), with 23 of 41 SSM 17of 27 NM, and oneof
one LMM carrying the mutation. In most cases, mutations
present in the primary tumors were also found in the cor-
responding metastases, and mutations were not found in
metastases arising from primary tumors without a BRAF
mutation.
Maldonado et al (2003) identified BRAF mutations in 19
of 39 SSM, one of four NM, three of 23 AM, one of nine
Figure 2
Identification of mutation V600E in primary melanoma tumor tis-
sue. Sequence analysis of PCR-amplified somatic DNA from tumor
sample Braf30.
Figure1
Identification of mutation V600E
by dHPLC. dHPLC WAVE analysis
of PCR-amplified somatic DNA
from tumor sample Braf19. Tumor
DNA was amplified using intronic
primer pair BRAF exon 15. All elut-
ion profiles that were abnormal
were identical in pattern to each
other.
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LMM and eight of 40 unclassified melanomas, and report a
higher prevalence of primary melanomas with BRAF muta-
tions from intermittently sun-exposed sites.
Reifenberger et al (2004) identified BRAF mutations in
two of four AM, five of eight NM, zero of two SSM, and zero
of one polypoid melanoma.
Recently Sasaki et al (2004) reported in this journal BRAF
mutations in nine of 35 primary melanomas (26%). Four of
eight (50%) SSM and five of 15 (33%) of AM had the mu-
tation, but none of six NM, five LMM or one mucosal me-
lanoma. Cohen et al (2004), Edwards et al (2004), and
Helmke et al (2004) have together analyzed 40 mucosal
melanomas and found the V600E mutation in only one case.
Our only mucosal melanoma showed the mutation and it
may be of relevance that the primary melanoma was on the
light-exposed lip.
If the results from these studies and our observations
reported in this paper are pooled, it appears that whereas
BRAF mutations are more prevalent in SSM and NM, they
are also present in a proportion of LMM and AM. Thus
BRAF mutations are predominantly associated with me-
lanomas arising on intermittently sun-exposed skin rather
than those arising on continually exposed skin or totally
non-exposed mucosal sites.
In conclusion, cumulative data show that the BRAF gene
is mutated in 20%–80% of primary melanomas, although all
reports to date involve relatively small numbers of primary
















Braf1 53 M SSM Scalp 6.8 V600E
Braf2 70 M SSM Trunk 6.0 V600E
Braf3 58 M SSM Trunk 3.8 V600E
Braf4 48 M SSM Neck 5.7 V600E
Braf5 66 M SSM Back 3.5 V600E
Braf6 69 F SSM Leg 6.3 WT
Braf7 76 F SSM Arm 2.0 WT
Braf8 65 F SSM Leg 2.9 WT
Braf9 75 F SSM Leg 18.0 WT
Braf10 53 M SSM Back 2.6 WT
Braf11 76 M SSM Face 5.4 WT
Braf12 80 M SSM Ear 5.8 WT
Braf13 76 F SSM Face 15.2 WT
Braf14 45 M SSM Cheek 2.5 WT
Braf15 52 F SSM Leg 11.8 WT
Braf16 62 M SSM Leg 9.9 WT
Braf17 54 F SSM Leg 4.9 WT
FTA 72 M SSM Back 3.5 FTA
Braf18 71 F Nodular Leg 10.0 V600E
Braf19 69 M Nodular Upper
arm
6.0 V600E
Braf20 70 F Nodular Thigh 4.9 V600E
Braf21 76 F Nodular Face 3.5 WT
Braf22 86 F Nodular Leg 14.6 WT
Braf23 87 F Nodular Buttock 5.0 WT
Braf24 82 F Nodular Back 6.0 WT
Braf25 66 M Nodular Foot 22.0 WT
Braf26 82 M Nodular Scalp 6.0 WT
Braf27 51 F Nodular Ear 3.0 WT
Braf28 71 M Nodular Scalp 9.0 WT
Braf29 72 M Acral Toe 3.5 V600E
Braf30 65 F Acral Leg 4.2 V600E
Braf31 61 M Acral Ankle 5.8 WT
Braf32 77 M Acral Leg 10.0 WT
Braf33 69 F Acral Sole 11.5 WT
Braf34 66 M Acral Toe 3.3 WT
Braf35 45 F Acral Leg 4.2 WT
Braf36 87 F Acral Sole 6.1 WT
Braf37 74 M Acral Sole 9.3 WT
Braf38 78 F Acral Leg 0.6 WT

















Braf40 80 M Acral Sole 5.5 WT
Braf41 74 M Acral Leg 4.2 WT
FTA 64 M Acral Leg 2.9 FTA
FTA 52 F Acral Foot 7.0 FTA
FTA 61 F Acral Leg 1.6 FTA
FTA 49 F Acral Leg 3.4 FTA
Braf42 72 M Mucosal Lip 7.5 V600E
Braf43 40 F LMM Face 1.0 V600E
Braf44 79 M LMM Foot 1.2 V600E
Braf45 76 M LMM Face 6.1 WT
Braf46 61 M LMM Face 9.5 WT
Braf47 88 M LMM Face 4.3 WT
Braf48 74 M LMM Face 8.4 WT
Braf49 73 F LMM Face 2.7 WT
Braf50 58 F LMM Neck 1.0 WT
Braf51 73 M LMM Ear 1.1 WT
Braf52 72 M LMM Face 3.9 WT
BRAF, v-raf murine sarcoma viral oncogene homolog B1; FTA, failed to
amplify; SSM, superficial spreading melanoma; LMM, lentigo maligna
melanoma; WT, wild-type.
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melanomas. From these data and that relating to the pres-
ence of BRAF mutations in non-progressor benign nevi, it
would appear that although mutations in the BRAF gene
develop in some benign melanocytic lesions, additional
events are needed for progression to melanoma. Converse-
ly, the absence of mutations in a proportion of primary and
metastatic melanomas indicate that there are alternative
genetic pathways to melanoma.
Materials and Methods
DNA for this study was extracted from paraffin-embedded spo-
radic primary melanoma samples. Ethical committee permission
(reference number LREC 00/161(2)) was obtained and written con-
sent given by participants, all of whom were Caucasians resident in
Scotland. The study was conducted according to the Declaration
of Helsinki principles.
Samples were obtained from 17 SSM, 11 NM, 13 AM, one mu-
cosal melanoma and ten LMM from 29 male patients and 23 fe-
male patients. The patient’s age at diagnosis ranged from 40–88 y
and Breslow thickness ranged from 0.6–22 mm (mean 6.3 mm,
median 5.6 mm). The primary tumors selected were relatively thick
because of the need to obtain an adequate volume of tumor tissue.
We defined constantly sun-exposed skin in this environment as the
head, neck, and hands in both sexes, and the female lower leg.
Intermittently exposed sites in our climate are the trunk and arms in
both sexes, and the legs in males.
Exon 15 BRAF mutation analysis
DNA extraction from parafﬁn-embedded tissue Ten 10 mM sections
of formalin-fixed paraffin-embedded primary melanoma tissue
were cut and deparaffinized in 1200 mL of Histo-Clear (National
Diagnostics, Hessle, UK). DNA was extracted using the QIAGEN
QIAamp DNA Mini kit (Qiagen, Sussex, UK) according to the man-
ufacturer’s instructions.
Denaturing HPLC analysis To identify the presence of mutant all-
eles a mutation screen of exon 15 was carried out by dHPLC using
the Transgenomic WAVE 3500 machine (Transgenomic, Glasgow,
UK). Optimum dHPLC temperatures were determined by a tem-
perature scan, using the WAVEMaker 4.0 melting profile for this
37.5% GC-rich fragment. Three mutation positive samples were








9 6 (67) Davies et al (2002)
5 4 (80) Pollock et al (2003)
10 2 (20) Cruz et al (2003)
28 7 (25) Dong et al (2003)
25 13 (52) Uribe et al (2003)
71 42 (59) Omholt et al (2003)
97 28 (29) Yazdi et al (2003)
115 32 (28) Maldonado et al (2003)
15 7 (47) Reifenberger et al (2004)
59 18 (30) Shinozaki et al (2004)
35 9 (26) Sasaki et al (2004)
469 168 (36) Total
52 13 (25) Lang and MacKie, this publication
BRAF, v-raf murine sarcoma viral oncogene homolog B1.














Omholt et al (2003) 69 23/41 17/27 ND 1/1 ND
56% 63%
Maldonado et al (2003) 75 19/39 1/4 3/23 1/9 ND
49% 25% 13% 11%
Reifenberger et al (2004) 15 0/2 5/9 2/4 ND ND
56% 50%
Sasaki et al (2004) 34 4/8 0/6 5/15 0/5 ND
50% 33%
Cohen et al (2004) 8 0/8
Edwards et al (2004) 13 0/13
Helmke et al (2004) 19 1/19
Lang and MacKie,
this publication
52 5/17 3/11 2/13 2/10 1/1 (lip)
(29%) (27%) (15%) (10%)
Total 244 51/107 26/57 12/55 4/25 2/41
(48%) (46%) (22%) (12%) (4.8%)
BRAF, v-raf murine sarcoma viral oncogene homolog B1; SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna
melanoma; ND, not done.
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originally run at four temperatures to determine the profile of the
mutated samples. The two best temperatures were chosen. For
exon 15 of BRAF, samples were run at 561C and 581C, although all
mutations were detected at 561C. After amplification, DNA was
eluted using a linear acetonitrile (Labscan, Dublin, Ireland) gradient
at a flow rate of 0.9 mL per min with the gradient duration adjusted
according to product length.
Sequence analysis Exon 15 of the BRAF gene and the flanking
splice junctions were amplified from the extracted DNA using
primer sequences (Davies et al, 2002) and PCR conditions previ-
ously described (Lang et al, 2003). The amplified DNA was sub-
jected to a second round of PCR amplification using the same
conditions. Agarose gel electrophoresis and ethidium bromide
staining confirmed the size and integrity of the expected 224 bp
amplified fragments. PCR products were purified directly from PCR
reaction mixtures using the QuickStep PCR Purification Kit (Ver. 4)
(Edge BioSystems, Gateshead, UK) and mixed with 0.8 mL of the
sequencing primer, 4 mL of ABI PRISM BigDye Terminator v3.1, 4 mL
of BetterBuffer (Microzone, Sussex, UK), and H2O to a final volume
of 20 mL. Samples were subjected to 25 cycles at 961C for 10 s,
501C for 5 s, and 601C for 4 min, followed by purification by ethanol
precipitation. Sequence analysis was carried out using an Applied
Biosystems ABI PRISM 3100 Genetic Analyzer (ABI, Warrington,
UK). Forward and reverse sequence electropherograms were gen-
erated by ABI Sequence Analysis 3.4.1 and analyzed using ABI
SeqScape versions 1.1 and 2.0. Each sequence was read at least
twice.
Allele-specific PCR In order to validate the above sequencing and
dHPLC results by only amplifying mutant DNA and to be able to
perform a rapid screen of paraffin-embedded primary melanoma
tissues, an allele-specific PCR was designed. For this study, the
same reverse primer as used previously and taken from Davies
et al (2002) was used along with an allele-specific forward primer
designed to only amplify DNA where the mutant V600E allele was
present, and a control forward primer to amplify any wild-type se-
quence. The primers were V600V F AATAGGTGATTTTGGTCTAGC-
TACAGT, which amplifies only wild-type BRAF and V600E F AATA-
GGGATTTTGGTCTAGCTACAGA, which amplifies only the V600E
mutant sequence. Amplification conditions were 1 cycle at 941C for
5 min, 30 cycles at 941C for 1 min, 571C for 1 min, 721C for 1 min,
and 1 cycle at 721C for 10 min.
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